Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GW’s Cannabidiol Drug To Be Funded In England For Epilepsy

More Data To Be Provided On Benefits And Safety

Executive Summary

GW Pharma’s cannabidiol drug Epidyolex can be funded on the NHS in England for seizures in patients with Dravet syndrome or Lennox-Gastaut syndrome. The company will have to provide additional data to address a number of uncertainties, including the waning of treatment effect, while more safety data are expected from an ongoing study.

You may also be interested in...



England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity

Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.

Swiss Finally Beat EMA On New Drug Approval Times

More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.

UK Beefs Up Health Security Body With New Vaccine Supply Role

The UK government says that the UKHSA will be able to “harness the strengths” of the Vaccines Taskforce, including its “excellent relationships with industry” and “expertise in innovation.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel